Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Activity of Ceftolozane-Tazobactam and Comparators against Pseudomonas aeruginosa from Patients in Different Risk Strata -- SMART United States 2016-2017.

Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2019 Jul 24. pii: S2213-7165(19)30183-3. doi: 10.1016/j.jgar.2019.07.017. [Epub ahead of print]

PMID:
31351246
2.

Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017.

Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF.

Diagn Microbiol Infect Dis. 2019 Oct;95(2):212-215. doi: 10.1016/j.diagmicrobio.2019.05.001. Epub 2019 May 8.

PMID:
31174995
3.

Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17.

Lob SH, Karlowsky JA, Young K, Motyl MR, Hawser S, Kothari ND, Gueny ME, Sahm DF.

J Antimicrob Chemother. 2019 Aug 1;74(8):2284-2288. doi: 10.1093/jac/dkz191.

PMID:
31086960
4.

Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016.

Karlowsky JA, Lob SH, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2018 Dec;15:140-147. doi: 10.1016/j.jgar.2018.07.012. Epub 2018 Jul 30.

PMID:
30071354
5.

Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.

Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.

J Glob Antimicrob Resist. 2018 Dec;15:12-19. doi: 10.1016/j.jgar.2018.05.017. Epub 2018 May 29.

PMID:
29857057
6.

In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.

Karlowsky JA, Lob SH, Kazmierczak KM, Young K, Motyl MR, Sahm DF.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00169-18. doi: 10.1128/AAC.00169-18. Print 2018 Jul.

7.

Activity of Ertapenem against Enterobacteriaceae in seven global regions-SMART 2012-2016.

Lob SH, Hackel MA, Hoban DJ, Young K, Motyl MR, Sahm DF.

Eur J Clin Microbiol Infect Dis. 2018 Aug;37(8):1481-1489. doi: 10.1007/s10096-018-3274-y. Epub 2018 May 12.

PMID:
29754209
8.

In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme.

Karlowsky JA, Lob SH, Kazmierczak KM, Hawser SP, Magnet S, Young K, Motyl MR, Sahm DF.

J Antimicrob Chemother. 2018 Jul 1;73(7):1872-1879. doi: 10.1093/jac/dky107.

PMID:
29659861
9.

Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

Braz J Infect Dis. 2017 May - Jun;21(3):343-348. doi: 10.1016/j.bjid.2017.03.006. Epub 2017 Apr 8.

10.

In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).

Lob SH, Hackel MA, Kazmierczak KM, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02209-16. doi: 10.1128/AAC.02209-16. Print 2017 Jun.

11.

In Vitro Activity of Imipenem against Carbapenemase-Positive Enterobacteriaceae Isolates Collected by the SMART Global Surveillance Program from 2008 to 2014.

Karlowsky JA, Lob SH, Kazmierczak KM, Badal RE, Young K, Motyl MR, Sahm DF.

J Clin Microbiol. 2017 Jun;55(6):1638-1649. doi: 10.1128/JCM.02316-16. Epub 2017 Mar 15.

12.

Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program.

Lob SH, Hackel MA, Kazmierczak KM, Hoban DJ, Young K, Motyl MR, Karlowsky JA, Sahm DF.

Diagn Microbiol Infect Dis. 2017 Jun;88(2):171-176. doi: 10.1016/j.diagmicrobio.2017.02.018. Epub 2017 Mar 2.

PMID:
28291628
13.

Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.

Karlowsky JA, Hoban DJ, Hackel MA, Lob SH, Sahm DF.

J Med Microbiol. 2017 Jan;66(1):61-69. doi: 10.1099/jmm.0.000421. Epub 2017 Feb 22.

PMID:
28051952
14.

Reassessing the Association between WIC and Birth Outcomes Using a Fetuses-at-Risk Approach.

Fingar KR, Lob SH, Dove MS, Gradziel P, Curtis MP.

Matern Child Health J. 2017 Apr;21(4):825-835. doi: 10.1007/s10995-016-2176-9.

PMID:
27531011
15.

Discrepancy between genotypic and phenotypic extended-spectrum β-lactamase rates in Escherichia coli from intra-abdominal infections in the USA.

Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF.

J Med Microbiol. 2016 Sep;65(9):905-9. doi: 10.1099/jmm.0.000307. Epub 2016 Jul 8.

PMID:
27392786
16.

Susceptibility patterns and ESBL rates of Escherichia coli from urinary tract infections in Canada and the United States, SMART 2010-2014.

Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahm DF.

Diagn Microbiol Infect Dis. 2016 Aug;85(4):459-65. doi: 10.1016/j.diagmicrobio.2016.04.022. Epub 2016 May 6.

PMID:
27306116
17.

Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii.

Lob SH, Hoban DJ, Sahm DF, Badal RE.

Int J Antimicrob Agents. 2016 Apr;47(4):317-23. doi: 10.1016/j.ijantimicag.2016.01.015. Epub 2016 Mar 5.

PMID:
27020541
18.

Epidemiology and Antimicrobial Susceptibility of Gram-Negative Pathogens Causing Intra-abdominal Infections in Pediatric Patients in Europe-SMART 2011-2014.

Lob SH, Badal RE, Hackel MA, Sahm DF.

J Pediatric Infect Dis Soc. 2017 Mar 1;6(1):72-79. doi: 10.1093/jpids/piv109.

PMID:
26883618
19.

Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013.

Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF.

J Glob Antimicrob Resist. 2015 Sep;3(3):190-197. doi: 10.1016/j.jgar.2015.05.005. Epub 2015 Jul 6.

PMID:
27873708
20.

Characterization of extended-spectrum beta-lactamases and antimicrobial resistance of Klebsiella pneumoniae in intra-abdominal infection isolates in Latin America, 2008-2012. Results of the Study for Monitoring Antimicrobial Resistance Trends.

Kazmierczak KM, Lob SH, Hoban DJ, Hackel MA, Badal RE, Bouchillon SK.

Diagn Microbiol Infect Dis. 2015 Jul;82(3):209-14. doi: 10.1016/j.diagmicrobio.2015.03.025. Epub 2015 Apr 9.

PMID:
25956930
21.

Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013.

Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, Sahm DF.

Antimicrob Agents Chemother. 2015;59(6):3606-10. doi: 10.1128/AAC.05186-14. Epub 2015 Mar 23.

23.

Epidemiology and susceptibility of Gram-negative appendicitis pathogens: SMART 2008-2010.

Lob SH, Badal RE, Bouchillon SK, Hawser SP, Hackel MA, Hoban DJ.

Surg Infect (Larchmt). 2013 Apr;14(2):203-8. doi: 10.1089/sur.2012.034. Epub 2013 Mar 29.

PMID:
23540793
24.

Promoting best-care practices in childhood asthma: quality improvement in community health centers.

Lob SH, Boer JH, Porter PG, Núñez D, Fox P.

Pediatrics. 2011 Jul;128(1):20-8. doi: 10.1542/peds.2010-1962. Epub 2011 Jun 13.

PMID:
21669890
25.

Evaluation of an arthritis communication campaign to promote physical activity in two cities.

Boardman AM, Lob SH, Fineman N, Ford-Keach P, Fox P.

Health Promot Pract. 2011 Jan;12(1):116-25. doi: 10.1177/1524839909331554. Epub 2009 Mar 25.

PMID:
19321885
27.

Case management: a controlled evaluation of persons with diabetes.

Lob SH, Kohatsu ND.

Clin Perform Qual Health Care. 2000;8(2):105-11. Erratum in: Clin Perform Qual Health Care 2000;8(4):191.

PMID:
11184051

Supplemental Content

Support Center